Group 1 - The company, Xinghao Pharmaceutical, announced the receipt of a termination notice from the National Medical Products Administration regarding its drug registration application for Oseltamivir Phosphate Oral Disintegrating Tablets [2] - The notice indicates that the company has been granted approval to withdraw its registration application for the mentioned drug [2] - This development may impact the company's product pipeline and future revenue potential in the antiviral segment [2] Group 2 - The withdrawal of the application suggests potential regulatory challenges or strategic shifts within the company [2] - The decision reflects the company's ongoing efforts to align its product offerings with market demands and regulatory requirements [2] - The pharmaceutical industry may see similar trends as companies navigate complex regulatory landscapes [2]
星昊医药：关于公司撤回药品注册申请的进展公告